# Dynavax Technologies

> Dynavax Technologies is an Emeryville, California biopharmaceutical company built around CpG 1018, a proprietary vaccine adjuvant that sharpens the immune system's response. Its flagship product, HEPLISAV-B, is the first and only two-dose adult hepatitis B vaccine approved in the U.S. and Europe, and had grown to roughly 44% U.S. market share by the end of 2024. Beyond hepatitis B, Dynavax licenses CpG 1018 to other vaccine developers - most visibly as an ingredient in several COVID-19 vaccines - and has advanced its own pipeline in shingles, plague, pandemic influenza, and Lyme disease. In December 2025 Sanofi agreed to acquire Dynavax for about $2.2 billion; the deal closed in February 2026.

- **Founded:** 1996
- **Headquarters:** Emeryville, California, United States
- **Founders:** Dino Dina (Co-founder, former President & CEO), Lawrence Steinman (Co-founder)
- **Team size:** ~410 employees
- **Products:** HEPLISAV-B, CpG 1018 adjuvant, Z-1018 shingles vaccine (investigational), Plague vaccine (investigational), Pandemic influenza and Lyme disease programs (investigational)
- **Notable:** Developed and won FDA (2017) and European (2021) approval for HEPLISAV-B, the first two-dose adult hepatitis B vaccine., Grew HEPLISAV-B to approximately 44% U.S. adult hepatitis B market share by end of 2024., CpG 1018 adjuvant used in COVID-19 vaccines administered to hundreds of millions of people globally.

## Products & services

- **HEPLISAV-B** — The first and only two-dose adult hepatitis B vaccine approved in the U.S. and Europe, offering superior seroprotection versus standard three-dose regimens in pivotal trials.
- **CpG 1018 adjuvant** — A proprietary toll-like receptor 9 (TLR9) agonist adjuvant that enhances vaccine immune response, licensed to other biopharmaceutical companies including for COVID-19 vaccines.
- **Z-1018 shingles vaccine (investigational)** — A shingles vaccine candidate for adults 50+ being tested head-to-head against Shingrix in a Phase 1/2 trial.
- **Plague vaccine (investigational)** — A CpG 1018-adjuvanted plague vaccine developed in collaboration with the U.S. Department of Defense, advancing to Phase 2.
- **Pandemic influenza and Lyme disease programs (investigational)** — Earlier-stage pipeline programs leveraging the CpG 1018 adjuvant platform.

## Achievements

- Developed and won FDA (2017) and European (2021) approval for HEPLISAV-B, the first two-dose adult hepatitis B vaccine.
- Grew HEPLISAV-B to approximately 44% U.S. adult hepatitis B market share by end of 2024.
- CpG 1018 adjuvant used in COVID-19 vaccines administered to hundreds of millions of people globally.
- Achieved $277.2 million in total 2024 revenue with a profitable commercial franchise.
- Reached a $2.2 billion acquisition by Sanofi, a 39% premium to the pre-announcement share price.

## Latest updates

- **2026-02** — Sanofi completed its acquisition of Dynavax; the company became an indirect wholly owned subsidiary of Sanofi.
- **2025-12** — Sanofi agreed to acquire Dynavax for $15.50 per share in cash, about $2.2 billion total equity value.
- **2025-08** — Top-line immunogenicity and safety data anticipated for the Z-1018 shingles candidate versus Shingrix (Phase 1/2).
- **2025-05** — Reported Q1 2025 financial results and announced new pipeline programs in pandemic influenza and Lyme disease.
- **2025-02** — Reported full-year 2024 results: $277.2M total revenue and ~44% HEPLISAV-B U.S. market share.

## Links

- Website: https://dynavax.com
- LinkedIn: https://www.linkedin.com/company/dynavax-technologies
- Twitter/X: https://twitter.com/DynavaxCorp

---

Profile page: https://yespress.io/dynavax-technologies
Published by YesPress — https://yespress.io
Last updated: 2026-07-15